Completed PHASE2 INTERVENTIONAL 2-arm NCT00663936

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

A Phase 2a Multi-center, Randomized, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of T-817MAa in Patients With Mild to Moderate Alzheimer's Disease

Sponsor: FUJIFILM Toyama Chemical Co., Ltd.

Conditions Alzheimer's Disease

Interventions Placebo T-817MA

Updated 9 times since 2017 Last updated: Oct 9, 2013 Started: Apr 30, 2008 Primary completion: May 31, 2011 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Alzheimer's Disease and is currently completed. FUJIFILM Toyama Chemical Co., Ltd. leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Nov 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Nov 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

FUJIFILM Toyama Chemical Co., Ltd.

Data source: FUJIFILM Toyama Chemical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, United States , Boynton Beach, United States , Brooklyn, United States , Charlotte, United States , Columbus, United States , Denver, United States , Durham, United States , Garden Grove, United States , Hamden, United States , Indianapolis, United States and 23 more locations